Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists

Antiviral Chemistry and Chemotherapy, Supplement

Volumn 12, Issue 1, 2001, Pages 19-31

  De Clercq, E ^a   Schols, D ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AMD3100; Antagonist; CCR5; CXCR4; HIV coreceptor

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4,4' [CARBONYLBIS[IMINO 1H PYRROLE 4,2 DIYLCARBONYLIMINO(1 METHYL 1H PYRROLE 4,2 DIYL)CARBONYLIMINO]]BIS(1,7 NAPHTHALENESULFONIC ACID); ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMD 2763; AMD 3479; AMINOOXYPENTANE RANTES; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE; CHEMOKINE DERIVATIVE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLAM DERIVATIVE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; N NONANOYL RANTES; POLYPHEMUSIN DERIVATIVE; POLYPHEMUSIN[5,12 TYROSINE 7 LYSINE]; PROTEINASE; RANTES; RECEPTOR BLOCKING AGENT; RNA DIRECTED DNA POLYMERASE; STROMAL CELL DERIVED FACTOR 1; T 134; T 22; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; VIRUS CELL INTERACTION; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; OLIGOPEPTIDES; RECEPTORS, CCR5; RECEPTORS, CXCR4;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034817270     PISSN: 13502816     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (101)

1. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion co-factor for macrophage-tropic HIV-1
2. HIV coreceptor downregulatlon as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication
3. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure
4. HIV blocked by chemokine antagonist
5. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
6. A new classification for HIV-1
7. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
8. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist
9. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
10. Synthesis and structure-activity relationships of phenylenebis(methylene)linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker
11. Synthesis and structure-activity relationships of phenylenebis(methylene) linked bis-tetraazamacrocycles that inhibit HIV replication. 2. Effect of heteroaromatic linkers on the activity of bicyclams
12. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4
13. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
14. Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog
15. Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV
16. + T cells
17. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
18. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES
19. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals
20. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry
21. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM3100), an inhibitor of infectious cell entry
22. Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1α, a potent ligand for the HIV-1 'fusin' coreceptor
23. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
24. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event
25. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100
26. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists
27. CD26, let it cut or cut it down
28. Identification of a major co-receptor for primary isolates of HIV-1
29. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding
30. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication
31. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120
32. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
33. Increased replication oft cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-chemokines
34. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
35. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
36. + cells is mediated by the chemokine receptor CC-CKR-5
37. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCRS
38. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and revention of emergence of the syncytium-inducing phenotype by blockade of CXCR4
39. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor
40. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
41. Dual effect of CCR5 Delta 32 gene deletion in HIV-1-infected patients
42. Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status
43. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo
44. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion
45. Sensitivity of human immunodeficiency virus infection to various α, β and γ chemokines
46. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication
47. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function
48. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
49. Quantitative structural activity relationship study of bis-tetraazacyclic compounds - A novel series of HIV-1 and HIV-2 inhibitors
50. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs
51. Dichotomous effects of beta-chemokines on HIV replication in monocytes and monocyte-derived macrophages
52. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
53. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: Role of signal transduction
54. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus
55. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100
56. Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
57. Opposite effects of SDF-1 on human immunodeficiency virus type 1 replication
58. 7]-polyphemusin II)
59. The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1-inhibiting chemokine
60. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32
61. CD40-mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: Potential role of B lymphocytes as a viral reservoir
62. Highly potent RANTES analogues either prevent CCRS-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
63. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection
64. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys7]polyphemusin II): A possible inhibitor of virus-cell fusion
65. LD78β, a non-allelic variant of human MIP-1cα_(LD78α, has enhanced receptor interactions and potent HIV suppressive activity
66. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T cell-line-adapted HIV-1
67. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions
68. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure
69. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCRS) for RANTES, MIP- 1β, and MIP-1α
70. The biology of chemokines and their receptors
71. HIV-1 coreceptor usage and CCR5 defective allele in mother-to-child transmission
72. Molecular cloning and functional expression of a new human CC-chemokine receptor gene
73. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
74. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression
75. Chemokines and HIV replication
76. Cellular receptors as targets for anti-human immunodeficiency virus agents
77. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4
78. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4
79. RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE)
80. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity
81. T cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show a switch in coreceptor use
82. The CXCR4 receptor antagonist, AMD3100, strongly inhibits HIV infection in SCID-hu PBMC mice
83. Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease
84. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety
85. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
86. CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages
87. Antiherpetic activities of N-α-acetyl-nona-D-arginine amide acetate
88. Signal sequence trap: A cloning strategy for secreted proteins and type I membrane proteins
89. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
90. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity
91. The role of CD26/DPP IV in chemokine processing
92. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
93. Selective CXCR4 antagonism by tat: Implications for in vivo expansion of coreceptor use by HIV-1
94. Enhanced anti-HIV-1 activity of CC-chemokine LD78β, a non-allelic variant of MIP-1α/LD78α
95. Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived factor 1β correlates with down-modulation of CXCR4
96. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: Two distinct mechanisms of HIV-1 dual tropism
97. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages
98. C-C chemokines, pivotal in protection against HIV type 1 infection
99. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?
100. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells
101. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II